## **LISTING OF THE CLAIMS**

Claims 1-19 (Canceled)

Claim 20 (New): A method of treating severe depression in a patient in need thereof comprising administering a daily pharmaceutically effective amount of escitalopram or a pharmaceutically acceptable salt thereof to the patient, wherein the daily dose of escitalopram or a pharmaceutically acceptable salt thereof is 10 mg or less.

Claim 21 (New): The method of claim 20, wherein the patient has a MADRS score of at least 29.

Claim 22 (New): The method of claim 20, wherein the daily dose is administered to obtain an effect in the patient after one week.

Claim 23 (New): The method of claim 21, wherein the daily dose is administered to obtain an effect in the patient after one week.

Claim 24 (New): The method of claim 20, wherein the daily dose is 10 mg of escitalopram or a pharmaceutically acceptable salt thereof.

Claim 25 (New): The method of claim 21, wherein the daily dose is 10 mg of escitalopram or a pharmaceutically acceptable salt thereof.

Claim 26 (New): The method of claim 20, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 28 (New): The method of claim 22, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 29 (New): The method of claim 23, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 30 (New): The method of claim 24, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 31 (New): The method of claim 25, wherein the pharmaceutically acceptable salt is an oxalate salt.

Claim 32 (New): The method of claim 26, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 33 (New): The method of claim 27, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim.34 (New): The method of claim 28, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 35 (New): The method of claim 29, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

Claim 36 (New): The method of claim 30, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

